Comparison of the efficacy between infliximab intravenous vs. subcutaneous in ulcerative colitis

Multicenter, randomized, open-label, prospective comparative study on the effect of subcutaneous and intravenous infliximab in bio-naive patients with moderate to severe ulcerative colitis (SUITE UC)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007789

Enrollment

Registered

2022-10-07

Start date

2022-10-17

Completion date

Unknown

Last updated

2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Biological/Vaccine, Non-Stem Cell : Intravenous or subcutaneous infliximab will be administered for 1 year in patients with moderate to severe ulcerative colitis who are randomly categorized at the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Moderate to severe ulcerative colitis

Exclusion criteria

Exclusion criteria: Patients who were exposed to other biologics. Patients who underwent bowel surgery.

Design outcomes

Primary

Measure	Time frame
Clinical remission	—

Secondary

Measure	Time frame
Clinical response	—

Countries

Korea, Republic of

Contacts

Public ContactEun Soo Kim

Kyungpook National University

dandy813@hanmail.net+82-53-200-5879

Outcome results